CoChat

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

Open access

The DOI matches its Crossref record, with a small difference in title or year; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these drugs on survival has not been determined. METHODS: We enrolled 1094 patients with chronic heart failure in a double-blind, placebo-controlled, stratified program, in which patients were assigned to one of the four treatment protocols on the basis of their exercise capacity. Within each of the four protocols patients with mild, moderate, or severe heart failure with left ventricular ejection fractions < or = 0.35 were randomly assigned to receive either placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor remained constant. Patient were observed for the occurrence death or hospitalization for cardiovascular reasons during the following 6 months, after the beginning (12 months for the group with mild heart failure). RESULTS: The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in risk attributable to carvedilol was 65 percent (95 percent confidence interval, 39 to 80 percent; P < 0.001). This finding led the Data and Safety Monitoring Board to recommend termination of the study before its scheduled completion. In addition, as compared with placebo, carvedilol therapy was accompanied by a 27 percent reduction in the risk of hospitalization for cardiovascular causes (19.6 percent vs. 14.1 percent, P = 0.036), as well as a 38 percent reduction in the combined risk of hospitalization or death (24.6 percent vs, 15.8 percent, P < 0.001). Worsening heart failure as an adverse reaction during treatment was less frequent in the carvedilol than in the placebo group. CONCLUSIONS: Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199605233342101

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 6

  1. Yue T-L, 1992, J Pharmacol Exp Ther, 263, 92
  2. Newton GE, 1995, Circulation, 92, I
  3. Bristow MR, 1992, J Am Coll Cardiol, 19, 146A
  4. Dhalla AK, 1994, Circulation, 90, I
  5. Sackner-Bernstein J, 1995, Circulation, 92, I
  6. Packer M, 1993, Circulation, 88, I

Cited by

See all 4,649

Metadata

Authors
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H.
Affiliations
  • Columbia University Irving Medical Center (US)
  • University of Minnesota (US)
  • Boston University (US)
  • Stanford University (US)
  • University of Utah (US)
Venue
New England Journal of Medicine
Published
1996-05-23
Volume
334
Issue
21
Pages
1349-1355
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2326508838
Cited by
4,649
References
35
Citations by year
2026: 26 · 2025: 75 · 2024: 75 · 2023: 87 · 2022: 96 · 2021: 107 · 2020: 87 · 2019: 86 · 2018: 97 · 2017: 115 · 2016: 118 · 2015: 117 · 2014: 101 · 2013: 125 · 2012: 121
FWCI
166.43
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Yale University
  • University of Southern California
  • Vanderbilt University
  • University of Miami
  • Ohio State University
  • University of Minnesota
  • Henry Ford Health System
  • Cleveland Clinic
  • Johns Hopkins University
  • University of Oklahoma
  • Georgetown University
  • University of Rochester
  • Temple University
  • Inova Health System
  • Vanderbilt University Medical Center
  • School of Medicine, Stanford University
  • Medical Center, University of Rochester
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
carvedilol, chronic heart failure, beta-blockers, mortality, cardiovascular hospitalization, exercise capacity, left ventricular ejection fraction, digoxin, diuretics, ACE inhibitors, worsening heart failure
MeSH terms
Carvedilol, Adrenergic alpha-Antagonists, Adrenergic beta-Antagonists, Carbazoles, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Propanolamines, Risk, Free Radical Scavengers, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. https://app.cochat.ai/papers/10.1056/nejm199605233342101
The paper
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996). The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejm199605233342101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.